Ventus Medical

The company's founders, Mark Dignum (CTO) and David Lawson (CRO), have extensive backgrounds in the pharmaceutical and medical device industries. They were part of the team responsible for developing e-VOKE, the first medically approved electronic cigarette. Dignum, a chemist by training and a qualified person in the European pharmaceutical industry, was instrumental in setting up a world-class manufacturing site for electronic nicotine delivery systems (ENDS). Lawson, a biochemist with an MBA, led the development of e-VOKE and established a regulatory consultancy.

Ventus Medical's primary business involves the research, development, and commercialization of medical devices. The company's current flagship product in development is ENHALE™, a next-generation nicotine replacement therapy (NRT) product. In May 2024, Ventus Medical submitted a UK Marketing Authorisation Application for ENHALE™, which is designed as a safer alternative to smoking and vaping. The device uses a proprietary low-temperature vaporization technology to deliver nicotine without the harmful byproducts associated with combustion or higher-temperature vaping products. It is CE marked as a medical device in the EU and is undergoing regulatory review in the UK and Europe.

Historically, Ventus Medical also developed and marketed Provent® Therapy, a non-invasive, disposable device for treating obstructive sleep apnea (OSA). This device utilized nasal expiratory positive airway pressure (EPAP) through a proprietary MicroValve technology to keep a patient's airway open during sleep. Provent received FDA clearance and was available in several countries before being discontinued in December 2020.